We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

10 Feb 2026 - 13 Feb 2026
17 Apr 2026 - 21 Apr 2026

Aggressive New HIV Strain Leads to AIDS Faster

By LabMedica International staff writers
Posted on 11 Dec 2013
A new aggressive strain of human immunodeficiency virus (HIV) develops more rapidly into acquired immunodeficiency syndrome (AIDS) than other current strains.

Human immunodeficiency virus type 1 (HIV-1) is characterized by a high genetic diversity, a consequence of an extremely high replication rate, an error-prone reverse transcriptase, recombination events during replication, and host selective immune pressure. More...
HIV-1 is divided into subtypes and the impact circulating recombinant forms (CRFs) need to be investigated.

Scientists at the Lund University (Sweden) analyzed blood samples obtained from individuals enrolled in a cohort comprising police officers in Guinea-Bissau. The cohort includes 225 HIV-1 seroincident individuals with estimated dates of seroconversion, defined as the midpoint between the last seronegative and the first seropositive sample. In total, samples were available for 191 individuals.

Viral ribonucleic acid (RNA) was extracted from blood plasma samples amplified by reverse-transcription polymerase chain reaction, and the C2–V3 region (460 bp) sequenced. Clones were amplified using Platinum Taq DNA Polymerase High Fidelity (Invitrogen, Carlsbad, CA, USA) and conventional M13 primers (−20 and −24) and sequenced using primers JA170, JA169 or M13 reverse primer.

The major subtypes/CRFs identified were CRF02_AG (53%), A3 (29%), and A3/02 (a recombinant of A3 and CRF02_AG) (13%). Infection with A3/02 was associated with a close to three-fold increased risk of AIDS and AIDS-related death compared to A3, respectively. The estimated time from seroconversion to AIDS and AIDS-related death was 5 and 8 years for A3/02, 6 and 9 years for CRF02_AG, and 7 and 11 years for A3.

Patrik Medstrand, PhD, professor of Clinical Virology at Lund University, said, “HIV is an extremely dynamic and variable virus. New subtypes and recombinant forms of HIV-1 have been introduced to our part of the world, and it is highly likely that there are a large number of circulating recombinants of which we know little or nothing. We therefore need to be aware of how the HIV-1 epidemic changes over time.” The study was published in the November 2103 issue of the Journal of Infectious Diseases.

Related Links:

Lund University
Invitrogen 



Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gel Cards
DG Gel Cards
New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Immunofluorescence image of reactive astrocytes (red) in the area surrounding sEcad-high cancer cells (blue, center) (Photo courtesy of Debeb Laboratory)

Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis

Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.